Pierre Fabre restructures ailing pharma business
This article was originally published in Scrip
Executive Summary
Just over a year after the death of its eponymous founder, French health and beauty firm Pierre Fabre has announced restructuring plans that include radical action and 551 job losses in its ailing pharma business, most of which will be in France. The company intends to focus its pharma business on three key therapy areas: oncology, neuropsychiatry and dermatology, with a fourth business unit dedicated to consumer healthcare.